Courses and Workshops

BioISI Research Seminar, April 4 – Daniel Santos, 11h30, FCiências.ID Amphitheatre

Home/Agenda, BioISISeminar/BioISI Research Seminar, April 4 – Daniel Santos, 11h30, FCiências.ID Amphitheatre

BioISI Research Seminar, April 4 – Daniel Santos, 11h30, FCiências.ID Amphitheatre

FCiências.ID Amphitheatre – April 4th , 11h

Daniel Santos

REQUIMTE | iMed

ABC Transporters in Health and Disease: Multidrug Resistance and Cystic Fibrosis

Daniel J. V. A. dos Santos1,2

1 LAQV@REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 4169-007 Porto, Portugal. 2 iMed.ULisboa, Faculty of Pharmacy, University of Lisboa, Avenida Prof. Gama Pinto, 1649-003 Lisboa, Portugal.

Email: ddsantos@fc.up.pt

ATP-binding cassette (ABC) proteins are ubiquitous super-family of membrane transporters present in all phyla with 7 sub-families (A-G) playing central roles in drug disposition, metabolism and pharmacokinetics. They are flexible transporters that act with the membrane environment to efflux undesirable metabolites or xenobiotic drugs from inside the cell providing this way a highly relevant protective role. At least 11 transporters of the ABC family have well characterized roles in human diseases while others are expressed in many tissues and appear to be particularly related with multidrug resistance (MDR) in cancer.

Although multifactorial in nature, multidrug resistance to chemotherapy regimens can be achieved by selecting phenotypes that over-express ABC transporters. The over-expression of P-glycoprotein (Pgp/ABCB1), multidrug resistance protein 1 (MRP1/ABCC1) or breast cancer resistance protein (BCRP/ABCG2) were found to be markers of overall poor chemotherapy response and prognosis in various cancers. For instance, Pgp is a single polypeptide of ∼170 kDa and effluxes a wide-range of substrates through an ATP-dependent mechanism and is found at the apical surface of kidney proximal tubule cells, canalicular membrane of hepatocytes, pancreas, villous intestinal cells, and blood–tissue barriers (e.g., brain, placenta, testis).

We developed a new research line to discover the main physicochemical features responsible for modulation through a new pharmacophore/QSAR1 with a better classification capability and, with the appearance in 2009 of the murine P-gp structure, this structural information was used through molecular simulations to study the dynamics of the transporter, how drug efflux occurs and how drug adsorption may affect P-gp activity. The characterization of three drug binding sites was achieved by matching experimental information with extensive docking results to unravel elusive drug/Pgp recognition, interactions and modulation mechanisms. A computational classification scheme was proposed to organize molecules in different class types (modulators, substrates, non-substrates). The access of drugs to the drug-binding pocket through a hypothesized gate was also investigated.2

Unfortunately, all Pgp modulators entering phase III clinical trials failed by showing a dramatic increase in cellular toxicity (tariquidar) or reduced in vivo effectiveness (zosuquidar, laniquidar). Thus, the problem resides elsewhere, namely in the polyspecificity of the binding sites. All these findings will be reviewed, discussed and linked with very recent findings as new emerging strategy to overcome the problems found in clinical trials.3 Finally, applications and relevance to other efflux pumps of the same familly, e.g. ABCC7 misfolding responsible for cystic fibrosis will be presented and discussed.

Acknowledgments: Fundação para a Ciência e Tecnologia is acknowledge for financial support (PTDC/QEQ-MED/0905/2012, UID/DTP/ 04138/2013). This work also received financial support by national funds, and was co-financed by the European Union (FEDER) over PT2020 Agreement (projects UID/ QUI/50006/2013 and POCI/01/0145/FEDER/007265).

References:

  • a) Ferreira R. J.; dos Santos, D. J. A.; Ferreira, M.-J. U.; Guedes, R. C. J. Chem. Inf. Model. 2011, 51, 1315. b) Baptista, R.; Ferreira, R. J.; dos Santos, D. J.; Fernandes, M. X.; Ferreira, M.-J. U. Futur. Med Chem 2016, 8, 629.
  • a) Ferreira, R. J.; Ferreira, M.-J. U.; dos Santos, D. J. A. J. Chem. Theory Comput. 2012, 8, 1853. b) Ferreira, R. J.; Ferreira, M. J. U.; dos Santos, D. J. V. A. J. Chem. Theory Comput. 2015, 11, 4525. c) Ferreira, R. J.; Ferreira, M.-J. U.; dos Santos, D. J. V. A. J. Chem. Inf. Model. 2013, 53, 1747. d) Ferreira, R. J.; Ferreira, M.-J. U.; dos Santos, D. J. V. A. Phys Chem Chem Phys. 2015, 17, 22023.3. Ferreira, R. J.; Ferreira, M.-J. U.; dos Santos, D. J. V. A. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2015, 5, 27.
  • Ferreira, R. J.; Bonito, C. A.; Ferreira, M.-J. U.; dos Santos, D. J. A. About P-glycoprotein: a new drugable domain is emerging from structural data. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2017, 7, e1316.
2019-04-18T15:19:00+00:00 March 29th, 2019|

About the Author: